About Cessation Therapeutics
Cessation Therapeutics is a company based in San Jose (United States) founded in 2017. Cessation Therapeutics has raised $6.76 million across 4 funding rounds from investors including HHS and National Institute on Drug Abuse. Cessation Therapeutics offers products and services including Anti-fentanyl Monoclonal Antibody. Cessation Therapeutics operates in a competitive market with competitors including MorphoSys, Genmab, Indivior, Forty Seven and Compass Therapeutics, among others.
- Headquarter San Jose, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cessation Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$6.76 M (USD)
in 4 rounds
-
Latest Funding Round
$1 M (USD), Series A
Mar 29, 2024
-
Investors
HHS
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cessation Therapeutics
Cessation Therapeutics offers a comprehensive portfolio of products and services, including Anti-fentanyl Monoclonal Antibody.
Antibody that captures fentanyl to prevent brain entry and overdose effects.
People of Cessation Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Cessation Therapeutics
Cessation Therapeutics has successfully raised a total of $6.76M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $1 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cessation Therapeutics
Cessation Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and National Institute on Drug Abuse.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Scientific research on drug use and addiction is supported.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Cessation Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cessation Therapeutics
Investment portfolio details for Cessation Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cessation Therapeutics
Detailed financials for Cessation Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cessation Therapeutics Comparisons
Peer comparison for Cessation Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cessation Therapeutics
Cessation Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MorphoSys, Genmab, Indivior, Forty Seven and Compass Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Antibody therapeutics for cancer and autoimmune diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for opioid addiction treatment are developed and commercialized.
|
|
| Locked | Locked | Locked |
Therapies for diverse diseases including oncology are developed.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer treatment are discovered and developed.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
Detailed competitors of Cessation Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cessation Therapeutics
Complete news archive for Cessation Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cessation Therapeutics
Cessation Therapeutics was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Cessation Therapeutics is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
John D Harkey is the current CEO of Cessation Therapeutics.
Cessation Therapeutics is a funded company, having raised a total of $6.76M across 4 funding rounds to date.
Cessation Therapeutics was founded in 2017 and is headquartered in San Jose, United States. Focus is placed on biotechnology for developing immunotherapy vaccines targeting addiction disorders, including those related to opioids, heroin, morphine, fentanyl, alcohol, and nicotine. Drug conjugate molecules are created by linking haptens to immunogenic proteins, which are then formulated with immune stimulants to generate antibodies against substances of abuse and support immunity induction.
Cessation Therapeutics's top competitors include Forty Seven, Indivior and Genmab.
Cessation Therapeutics offers Anti-fentanyl Monoclonal Antibody.
Cessation Therapeutics has 2 investors. Key investors include HHS, and National Institute on Drug Abuse.